Myriad Genetics (NASDAQ:MYGN) Releases FY 2025 Earnings Guidance

Myriad Genetics (NASDAQ:MYGN) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 0.070-0.110 for the period, compared to the consensus earnings per share estimate of 0.060. The company issued revenue guidance of $840.0 million-$860.0 million, compared to the consensus revenue estimate of $863.0 million.

Myriad Genetics Stock Performance

NASDAQ MYGN opened at $10.20 on Thursday. The firm has a market capitalization of $928.56 million, a P/E ratio of -7.85 and a beta of 1.88. Myriad Genetics has a fifty-two week low of $9.76 and a fifty-two week high of $29.30. The stock has a 50-day simple moving average of $13.15 and a two-hundred day simple moving average of $18.66. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.12). Myriad Genetics had a negative net margin of 14.09% and a negative return on equity of 4.51%. The firm had revenue of $210.60 million for the quarter, compared to analyst estimates of $210.35 million. During the same quarter in the prior year, the business posted ($0.12) EPS. On average, equities analysts forecast that Myriad Genetics will post -0.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

MYGN has been the topic of several research analyst reports. Leerink Partnrs lowered Myriad Genetics from a “strong-buy” rating to a “hold” rating in a report on Monday, December 9th. StockNews.com lowered shares of Myriad Genetics from a “buy” rating to a “hold” rating in a report on Saturday, March 1st. Craig Hallum began coverage on shares of Myriad Genetics in a report on Wednesday, February 12th. They set a “buy” rating and a $29.00 price objective on the stock. UBS Group dropped their target price on shares of Myriad Genetics from $18.00 to $16.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 25th. Finally, Stephens restated an “equal weight” rating and set a $20.00 price target on shares of Myriad Genetics in a research report on Thursday, January 16th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Myriad Genetics currently has an average rating of “Hold” and an average price target of $21.82.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.